This website contains information about Adtralza®, a medicine for the treatment of moderate to severe atopic dermatitis (also know as atopic eczema) in adults and adolescents 12 years and older. Here you can read about how Adtralza® works, what you need to know before you start taking it, information about possible side effects and a step-by-step guide on how to use it. You’ll also find answers to frequently asked questions about Adtralza®.

Before you start your treatment with Adtralza®, please take the time to read the patient information leaflet (PIL) that comes in the pack. This website does not replace the PIL.

For residents of the UK, the PIL is available online via the following links for the Adtralza® pre-filled pen and pre-filled syringe.
For residents of the Republic of Ireland, the PIL is available online via the following links for the Adtralza® pre-filled pen and pre-filled syringe.

Always refer to the PIL for full details and use Adtralza® exactly as your dermatology team have told you. If you have any questions, ask a member of your dermatology team.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Side effects reporting information can be found at the bottom of this page.

Treatment with Adtralza®

Learn more about Adtralza®
Adtralza swoosh

How to take Adtralza®

Adtralza® is given by injection under your skin (subcutaneous injection).

You and your doctor or nurse can decide if you can inject Adtralza® yourself.

Pre-filled Pen

Learn how to inject Adtralza® in this step-by-step video for the pre-filled pen.

Refer to the 'instructions for use' found in the Patient Information Leaflet (PIL) that comes in your Adtralza® pack for written instructions.

UK/IE MAT-70065
December 2023

Pre-filled Syringe

Learn how to inject Adtralza® in this step-by-step video for the pre-filled syringe.

Refer to the 'instructions for use' found in the Patient Information Leaflet (PIL) that comes in your Adtralza® pack for written instructions.

UK/IE MAT-62108
February 2023

FAQ bubbles

Adtralza® FAQs

Learn more about Adtralza® and find answers to commonly asked questions.

 

 

Get the answers
My LEO Pharma

My LEO Pharma

My LEO Pharma is designed to support you throughout your Adtralza® treatment journey – providing answers to those initial questions as you familiarise yourself with your treatment, and helping you get the most out of Adtralza®.

Reporting side effects

Adtralza®▼ (tralokinumab) is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

For the United Kingdom

You can also report side effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search MHRA Yellow Card in the Google Play or Apple App Store.

For the Republic of Ireland

The Health Products Regulatory Authority (HPRA) monitors the safety and quality of all medicines available in Ireland. Should you wish, you can also report any suspected side effects directly via HPRA Pharmacovigilance,
Earlsfort Terrace, IRL- Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; Email: medsafety@hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine.

Date of preparation: October 2024
UK/IE MAT-74847